COVID Affects Cancer Care, Patients' Mental Health Studies: fewer diagnoses, more severe disease, worse outcomes, distressed patients Jan 29, 2021
Montana Oncologist Fired for Misdiagnosing, Overtreating Patients But some rally around him Jan 26, 2021
Cancer and COVID; Booze and Cancer; 'Screech' Starts Chemo News, features, and commentary about cancer-related issues Jan 21, 2021
Targeted Combo Fails in EGFR-Mutant NSCLC Osimertinib-bevacizumab no better than osimertinib alone Jan 07, 2021
Baby Boys Get Cancer From Mom During Birth Report highlights potential fetal implications of undiagnosed maternal cervical cancer Jan 06, 2021
Lorlatinib Shows 'Striking' CNS Activity in ALK Lung Cancer But unusual adverse events may hold therapy back Nov 18, 2020
CDK4/6 Inhibitor in SCLC Cuts Chemo-Induced Myelosuppression Reduced severe neutropenia and less need for supportive care with trilaciclib Oct 20, 2020
Dual Checkpoint Blockade With Some Chemo Boosts OS in NSCLC Nivolumab-ipilimumab with two cycles of chemotherapy improved survival, regardless of histology or PD-L1 status Oct 17, 2020
Drug Active in 'Undruggable' KRAS-Mutant NSCLC Responses in a third of patients, disease control rate approaching 90% Sep 20, 2020
A Closer Look at FDA Decision to Pull Lorcaserin More cancers, multiple primaries, and deaths in CAMELLIA-TIMI 61 influenced agency decision Sep 09, 2020
In Lupus, Older Age and Male Sex Raise Cancer Risk Role of most medications, though, not yet clear Aug 21, 2020
Chemo-Free Regimen Boosts OS in Mesothelioma Big advantage for nivolumab-ipilimumab in nonepithelioid tumors drives advantage over chemo Aug 09, 2020
Another ALK Drug Tops Crizotinib in First-Line NSCLC Ensartinib doubled PFS over older standard, with improved CNS activity Aug 08, 2020
COVID-19 More Deadly Than Cancer Itself? Highlights from the AACR conference on COVID-19 and cancer Jul 24, 2020
The Serious Conversation: Delivering Bad News by Telemedicine As office visits move online, clinicians discuss breaking life-changing diagnoses virtually Jul 13, 2020
Cancer Immunotherapy Tied to Severe COVID-19 Outcomes Nearly threefold increased risk of hospitalization, severe respiratory illness Jun 25, 2020
Paradigm Shift Coming for Early NSCLC? Postoperative osimertinib doubles DFS in patients with stages Ib-IIIa EGFR+ lung cancer May 28, 2020
End of Life and COVID-19; DCIS Doubles Cancer Risk; Training for 'Bad News' News, features, and commentary about cancer-related issues May 28, 2020
6-Week Keytruda Safe, Effective in Melanoma Schedule gets FDA approval for all adult indications Apr 30, 2020
COVID-19 Mortality Spikes in Patients With Lung, Blood Cancers Those with metastatic disease also at special risk for poor outcomes Apr 28, 2020
How Prevalent Is Checkpoint Inhibitor Thyroid Dysfunction, Really? Real-world data offer word of caution for oncologists Apr 01, 2020
DOAC Works in Cancer-Related VTE, No Tradeoff in Bleeds Apixaban monotherapy matches dalteparin in non-inferiority trial Mar 29, 2020
No DNA Damage Seen With Single Low-Dose CT Scan Some reassurance for annual lung cancer screening safety Mar 10, 2020
PD-1 vs PD-L1 Inhibitors: Do Outcomes Differ? Meta-analysis suggests they aren't equivalent Dec 27, 2019
Pembrolizumab Shows Survival Benefit in KRAS-Mutant NSCLC Improved OS, PFS, and response rates compared to chemo in first-line Dec 16, 2019
AHA Dedicates $20 Million to Youth Vaping Research Association and partners aim to "hold e-cigarette companies publicly accountable for their lies" Nov 16, 2019
Rheumatoid Arthritis Is No Bar to Cancer Immunotherapy Small study finds flares common with checkpoint inhibitors, but few patients stopped treatment because of them Nov 13, 2019
Notable OS Gains with Dual Immunotherapy in Advanced NSCLC Secondary analysis of CheckMate 227 brings more good news for nivolumab-ipilimumab combo Sep 28, 2019
BCG Vax: A Shot Against Lung Cancer in Native Populations? 60-year follow-up data from a vaccine trial found surprising results Sep 25, 2019
Post-Immunotherapy SBRT Boosts Outcomes in Advanced NSCLC Increased systemic response rate, disease control rate, and PFS in phase II trial Sep 17, 2019
Anti-PD-1/L1 for NSCLC Sparks Talk of the 'C' Word Unprecedented survival at 3 and 5 years, but investigators reluctant to say "cure" Sep 10, 2019
'Dirtier' Drugs Step Aside in RET-Positive NSCLC Over two-thirds of patients respond to selective RET inhibitor Sep 09, 2019
TMB in Lung Cancer: 'Not Ready for Prime Time' No association between tumor mutational burden and outcomes in three trials Sep 09, 2019
Small Cancer Risk With Lung Micronodules Supports classifying small nodules as negative scan result Jul 10, 2019
More Clarity to Steroids' Effect on Anti-PD-1 Therapy Adverse effects driven by palliative indications associated with poor prognosis Jun 27, 2019